Stefan Weigand

Summary

Affiliation: F. Hoffmann-La Roche Ltd

Publications

  1. ncbi Minor structural modifications convert a selective PPARalpha agonist into a potent, highly selective PPARdelta agonist
    Stefan Weigand
    Bayer Health Care AG, Pharma Research, D 42096 Wuppertal, Germany
    Bioorg Med Chem Lett 15:4619-23. 2005
  2. doi Global quantitative phosphoproteome analysis of human tumor xenografts treated with a CD44 antagonist
    Stefan Weigand
    Discovery Oncology, Pharma Research and Early Development, Roche Diagnostics GmbH, Penzberg, Germany
    Cancer Res 72:4329-39. 2012
  3. pmc Targeting Tumor Cells with Anti-CD44 Antibody Triggers Macrophage-Mediated Immune Modulatory Effects in a Cancer Xenograft Model
    Daniela Maisel
    Translational Technologies and Bioinformatics, Pharmaceutical Sciences, Roche Innovation Center Munich, Penzberg, Germany
    PLoS ONE 11:e0159716. 2016
  4. doi CD44 Isoform Status Predicts Response to Treatment with Anti-CD44 Antibody in Cancer Patients
    Fabian Birzele
    Roche Innovation Center Penzberg, Pharmaceutical Sciences, Roche Pharmaceutical Research and Early Development, Penzberg, Germany
    Clin Cancer Res 21:2753-62. 2015
  5. ncbi Novel, selective indole-based ECE inhibitors: lead optimization via solid-phase and classical synthesis
    Michael Brands
    Bayer HealthCare AG, Business Group Pharma, Research and Development, D 42096 Wuppertal, Germany
    Bioorg Med Chem Lett 15:4201-5. 2005
  6. ncbi Selective indole-based ECE inhibitors: synthesis and pharmacological evaluation
    Michael Brands
    Bayer HealthCare AG, Business Group Pharma, Research and Development, Aprather Weg 18a, 42096 Wuppertal, Germany
    ChemMedChem 1:96-105. 2006

Collaborators

  • Jean Pierre Delord
  • Devalingam Mahalingam
  • Christoph Schaab
  • Kentaro Hashimoto
  • Christophe Le Tourneau
  • Fabian Birzele
  • Michael Brands
  • Daniela Maisel
  • Valeria Runza
  • Edgar Voss
  • Adam Nopora
  • Jens Kerim Ergüden
  • Christian Schröder
  • Stephan Siegel
  • Dirk Heimbach
  • Johannes Peter Stasch
  • Sabine Bader
  • Bernhard Goller
  • Thomas Friess
  • Daphna Laifenfeld
  • Michael Cannarile
  • Carla van Herpen
  • Henk Verheul
  • Andrew L Coveler
  • Konrad Honold
  • Florian Heil
  • Sabine Lohmann
  • Valérie Méresse
  • Hideki Tsujishita
  • Nagahiro H Yoshida
  • Thomas Krahn

Detail Information

Publications6

  1. ncbi Minor structural modifications convert a selective PPARalpha agonist into a potent, highly selective PPARdelta agonist
    Stefan Weigand
    Bayer Health Care AG, Pharma Research, D 42096 Wuppertal, Germany
    Bioorg Med Chem Lett 15:4619-23. 2005
    ..Compound 33 showed good pharmacokinetics...
  2. doi Global quantitative phosphoproteome analysis of human tumor xenografts treated with a CD44 antagonist
    Stefan Weigand
    Discovery Oncology, Pharma Research and Early Development, Roche Diagnostics GmbH, Penzberg, Germany
    Cancer Res 72:4329-39. 2012
    ..Taken together, our approach augments the value of other high throughput techniques to identify biomarkers for clinical development of targeted agents...
  3. pmc Targeting Tumor Cells with Anti-CD44 Antibody Triggers Macrophage-Mediated Immune Modulatory Effects in a Cancer Xenograft Model
    Daniela Maisel
    Translational Technologies and Bioinformatics, Pharmaceutical Sciences, Roche Innovation Center Munich, Penzberg, Germany
    PLoS ONE 11:e0159716. 2016
    ..e. macrophages) to the tumor site. We finally provide evidence for antibody-dependent cellular phagocytosis (ADCP) of the malignant cells by macrophages. ..
  4. doi CD44 Isoform Status Predicts Response to Treatment with Anti-CD44 Antibody in Cancer Patients
    Fabian Birzele
    Roche Innovation Center Penzberg, Pharmaceutical Sciences, Roche Pharmaceutical Research and Early Development, Penzberg, Germany
    Clin Cancer Res 21:2753-62. 2015
    ....
  5. ncbi Novel, selective indole-based ECE inhibitors: lead optimization via solid-phase and classical synthesis
    Michael Brands
    Bayer HealthCare AG, Business Group Pharma, Research and Development, D 42096 Wuppertal, Germany
    Bioorg Med Chem Lett 15:4201-5. 2005
    ..We report systematic optimization of this compound class by means of classical and solid-phase chemistry. Optimized compounds with a bisarylamide side chain at the 2-position of the indole skeleton exhibit low-nanomolar activity on ECE...
  6. ncbi Selective indole-based ECE inhibitors: synthesis and pharmacological evaluation
    Michael Brands
    Bayer HealthCare AG, Business Group Pharma, Research and Development, Aprather Weg 18a, 42096 Wuppertal, Germany
    ChemMedChem 1:96-105. 2006
    ..All ECE inhibitors of the indole class showed high selectivity for ECE over related metalloproteases such as NEP and ACE. Therefore, these compounds might have further potential as drugs for the treatment of coronary heart diseases...